Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
about
Mechanisms of resistance to anti-EGFR therapy in colorectal cancerThe Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside.Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.Subsequent anti-VEGF therapy after first-line anti-EGFR therapy improved overall survival of patients with metastatic colorectal cancer.Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma.Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab.
P2860
Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
@en
type
label
Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
@en
prefLabel
Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
@en
P2093
P2860
P50
P356
P1433
P1476
Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
@en
P2093
Angélique Chevriaux
Emeric Limagne
Jean David Fumet
Leila Bengrine
Romain Boidot
P2860
P304
P356
10.18632/ONCOTARGET.7008
P407
P577
2016-01-25T00:00:00Z